<DOC>
	<DOCNO>NCT00894452</DOCNO>
	<brief_summary>The purpose study describe clinical , pharmacokinetic genetic factor associate variance oral methadone dosage patient steady state heroin dependence maintenance treatment . The hypothesis investigator predict 70 % variance factor , include CYP 3A4 function measure oral midazolam challenge .</brief_summary>
	<brief_title>Variance Oral Methadone Dosage : Description Implicated Factors</brief_title>
	<detailed_description>Patients steady state methadone maintenance treatment may receive oral dosage range 5 130 mg per day clinical practice . This study aim provide comprehensive cross-sectional description factor involve variance : - comorbidity addictive psychiatric disorder - severity pre-existing heroin dependence - function CYP 3A4 enzyme assess oral midazolam challenge - genetic polymorphism enzymes implicate methadone pharmacokinetic pharmacodynamic ( CYPs , MDR1 , OPRM1 , COMT ) The expect result predictive equation oral methadone dosage steady state .</detailed_description>
	<mesh_term>Heroin Dependence</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>heroin dependence maintenance treatment methadone steady state : stable oral methadone dosage since 3 month least current heroin dependence abuse current cocaine and/or alcohol and/or sedatives dependence pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Methadone</keyword>
	<keyword>CYP</keyword>
	<keyword>OPRM1</keyword>
	<keyword>MDR1</keyword>
	<keyword>COMT</keyword>
	<keyword>Midazolam challenge</keyword>
</DOC>